Publications

Nail Toxicities Associated with Systemic Anticancer Therapy — Implications for Nursing Practice

Authored by leading Podiatrist Afni Shah-Hamilton, who has a special interest in cancer therapy nail damage and is a member of the Macmillan Allied Service Board. Published in the Cancer Nursing Practice Journal.

Download the paper

Polybalm Clinical Trial

Oncologist Professor Rob Thomas demonstrated Polybalm profoundly reduced chemotherapy-related nail damage and significantly improved nail-related quality of life. Published in the Journal of Breast Cancer Research.

Download the paper

The Economic Case for Polybalm

Health economist and former NICE committee member Prithwiraj Das, MBBS, MSc International Health Policy (LSE), developed an economic model showing that Polybalm prophylaxis is cost-neutral at a 10% nail toxicity incidence rate and cost-saving above it. At real-world incidence rates of up to 89%, the intervention yields net healthcare resource savings. Presented at ONS 2026.

Poster PDF Download the abstract